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Background: Troponin-T (TnT), high-sensitive C-reactive protein (hsCRP), and Brain Natri-
uretic Peptide (BNP) have been shown to be independent prognostic indicators of total and
cardiac death during short- and long-term follow-up.
Methods:We investigated prospectively the prognostic value of admission samples ofTnT,
hsCRP, and BNP in 871 chest-pain patients from South-Western Norway and 982 patients
from Northern Argentina, based on a similar protocol and database setup. Follow-up was
2 years for the pooled population. The prognostic value of the selected biomarkers was
investigated in quartiles of 239 patients with TnT values greater than 0.01 and up to and
including 0.1 ng/mL, with continuous TnT as a potential confounder.
Results: After 24 months, 69 patients had died, of whom 38 died from cardiac causes. In
the selected range of TnT, this biomarker was not significantly different between patients
who died and survived (mean 0.0452 and 0.0457, p=0.887). The BNP levels were sig-
nificantly higher among patients dying than in long-term survivors [340 (142–656) versus
157 (58–367) pg/mL (median, 25 and 75% percentiles), p< 0.001]. In a multivariable Cox
regression model for death within 2 years, the hazard ratio (HR) for BNP in the highest
quartile (Q4) as compared to the lowest (Q1) was significantly related to total mortality
[HR 2.84 (95% confidence interval (CI), 1.13–7.17)], p= 0.027, in addition to age (p≤0.001)
and hypercholesterolemia (p=0.043). For cardiac death, the HR for BNP was 5.18 (95%
CI, 1.06–25.3), p=0.042. Several other variables (age, congestive heart failure, ST ele-
vation myocardial infarction, and study country) were also significantly related to cardiac
death. In a multivariable Cox regression model, hsCRP rendered no significant prognostic
information for all-cause mortality (p=0.089) or for cardiac mortality (p=0.524).
Conclusion: In patients with borderlineTnT values (greater than 0.01 and up to and includ-
ing 0.1 ng/mL), this biomarker as well as hsCRP did not render prognostic information,
whereas BNP was found to be a strong prognostic indicator of 2-year total and cardiac
mortality.
Keywords: chest-pain, acute coronary syndrome, total mortality, cardiac mortality, biomarkers, troponin- T, brain
natriuretic peptide, high sensitivity C-reactive protein
INTRODUCTION
Several studies have employed troponins, BNP and hsCRP in risk
stratification of patients presenting with an acute coronary syn-
drome (ACS). An early paper taking into account these three
biomarkers in prognostication of later events had a follow-up of
10 months and was published by Sabatine et al. (1).
The troponins have become both a diagnostic and prog-
nostic tool in ACS (2, 3). However, this biomarker is sensitive
to myocardial damage, and so low serum values following an
attack of chest-pain may not only indicate a primary coronary
event, but may also be due to other conditions leading to its
release (4). Thus, its prognostic implications may be masked
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by multifactorial causality when released in low concentrations.
Accordingly, other biomarkers, such as hsCRP and BNP, may serve
as better prognostic tools in low troponin release conditions.
BNP is a counter-regulatory peptide hormone predominantly
synthesized in the ventricular myocardium. It is released into the
circulation in response to ventricular dilatation and pressure over-
load (5, 6). BNP is an established biomarker of left ventricular
dysfunction and heart failure (HF). It has also been shown to
provide prognostic information beyond and above left ventricular
ejection fraction (LVEF) in patients with ACS (7–13).
C-reactive protein (CRP) is an acute-phase reactant and a
marker for underlying systemic inflammation, irrespective of its
etiology, also reflecting atherosclerosis and plaque rupture (14–
16), when applying high sensitivity CRP assays (17). However,
the prognostic value of this marker in CVD is still controversial
(18–20), although supported by our latest study (13).
The aims of this study were to explore the ability of BNP
and hsCRP to predict risk of total and cardiac mortality within
24 months following the index event in a consecutively hospi-
talized chest-pain population with troponin release >0.01 and
≤0.1 ng/mL, pooling two populations with suspected ACS.
MATERIALS AND METHODS
This analysis is based on a two-center prospective follow-up
study [Risk in the Acute Coronary Syndrome (RACS), Clinical-
Trials.gov Identifier: NCT00521976 and Argentinean Risk Assess-
ment Registry in ACS (ARRA-RACS), ClinicalTrials.gov Identifier:
NCT01377402]. We recruited 871 consecutive chest-pain patients
with suspected ACS in RACS and 982 patients in ARRA-RACS,
consecutively admitted to the Emergency Department (ED) of
Stavanger University Hospital, Stavanger, Norway, and to nine hos-
pitals in Salta, Argentina, respectively. The same protocol and case
report form (CRF) was used in both studies. Both studies were
run between 2002 and 2011. The main exclusion criteria were age
<18 years or unwillingness or incapacity to provide informed con-
sent and prior inclusion in the present study. We used troponin-T
(TnT) levels at baseline and at 6 h after admission for disease classi-
fication. BNP and hsCRP were determined in all patients as quality
indicators in our registry.
Two-hundred and thirty nine patients with a troponin release
>0.01 and≤0.1 ng/mL were included in the present study. Patients
with missing values for BNP, hsCRP, or a potential confounder
were excluded from the multivariable Cox models. The primary
and secondary outcome measure was defined as all-cause mortal-
ity and cardiac mortality, respectively. Follow-up time was 2 years
from inclusion. Survival status, date and cause of death, and clini-
cal data were obtained by telephone interview at 30 days, 6, 12, and
24 months during the 2-year follow-up period. In case of incapac-
ity to provide information, the general practitioner or nursery
home were contacted to obtain relevant data. In addition, hospital
journals were searched for confirmation of reported data.
Clinical and laboratory parameters, including assessment of
previous myocardial infarction (MI), angina pectoris, congestive
heart failure (CHF), diabetes mellitus (defined as either whole
blood fasting glucose concentrations above 6.1 mmol/L, 2 h post
glucose load concentrations above 10.0 mmol/L, or medically
treated diabetes mellitus), smoking status, hypercholesterolemia
(defined as total cholesterol concentrations above 6.5 mmol/L
or medical treated hypercholesterolemia), and arterial hyperten-
sion (defined as repeated blood pressure measurements above
140/90 mmHg or treated hypertension) were based on hospital
records and personal interviews.
Electrocardiographic (ECG) findings at admission were clas-
sified according to the presence of ST-segment changes (i.e., ST-
segment depression or elevation, T-wave inversion, or left bundle-
branch block). The term ACS encompasses unstable angina (UAP),
non-ST-segment elevation myocardial infarction (NSTEMI), and
ST-segment elevation myocardial infarction (STEMI). In the
present substudy, we included all subjects with a troponin release
>0.01 and≤0.1 ng/mL, irrespective of this classification. However,
for the diagnosis of a MI, we applied a cut-off value of 0.05 ng/mL
in the Norwegian population and 0.03 ng/mL in the Argentinean
population.
Written informed consent was obtained from all patients. The
study was approved by the Ethics Committee at the Board of
Medical School of Salta, Argentina, and by the Regional Board of
Research Ethics and the Norwegian Health authorities, and con-
ducted in accordance with the Helsinki declaration of 1971, as
revised in 1983.
BLOOD SAMPLING PROCEDURES AND LABORATORY
MEASUREMENTS
Peripheral blood samples for determination of TnT, s-creatinine,
s-glucose, s-lipids, hsCRP, and BNP were drawn immediately fol-
lowing admission by direct venipuncture with a minimum of stasis
of an antecubital vein. A repeated blood sample for the deter-
mination of TnT was drawn 6–7 h following the primary blood
sample. Clotted whole blood and ethylene diamine tetraacetic acid
(EDTA) blood samples were centrifuged for 15 min with 2000× g
at 20°C without delay. Serum for hsCRP and EDTA plasma for
BNP were immediately frozen and stored at −80°C until the
measurements were performed. For all other biochemical para-
meters, measurements were performed immediately following
centrifugation.
Troponin-T was quantified in serum by a cardiac-specific
third-generation (Norwegian population) and fourth-generation
(Argentinean population) TnT ELISA assay from Roche Diagnos-
tics, using a high-affinity cardiac-specific TnT isoform antibody
(21). The lower limit of detection for the assays was 0.01 ng/mL.
We selected borderline TnT values >0.01 and ≤0.1 ng/mL for
prognostic evaluation.
BNP was analyzed in EDTA plasma using the microparticle
enzyme immunoassay (MEIA) Abbott AxSYM® (Abbott Lab-
oratories, Abbott Park, IL, USA). The dynamic range was 0–
4000 pg/mL and the within run coefficient of variation (CV) was
6.3% at 95 pg/mL and 4.7% at 1587 pg/mL.
High-sensitive C-reactive protein was measured with the use of
an immunoturbidimetric assay [Tina-quant® CRP (latex) high-
sensitive assay, Roche Diagnostics, Germany] performed on a
Roche automated clinical chemistry analyzer (MODULAR P).
The detection limit was 0.03 mg/L and the measuring range
0.1–20.0 mg/L with an extended measuring range with auto-
matic re-run 0.1–300 mg/L. The between-assay CV was 3.45% at
1.19 mg/L and 2.70% at 0.43 mg/L.
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Table 1 | Baseline characteristics according to BNP (pg/mL) quartiles.
Variable Total cohort a Q1 (n=57) Q2 (n=59) Q3 (n=57) Q4 (n=58) p-Value
Age, yearb 72.5±13.1 65.6±12.4 71.7±13.5 74.1±13.1 78.7±9.8 <0.001
Male gender, % (n) 61.9 (143) 64.9 (37) 67.8 (40) 54.4 (31) 60.3 (35) 0.473
Risk markers at baseline
Peak TnT (ng/mL)c 0.04 (0.02–0.06) 0.04 (0.03–0.07) 0.04 (0.02–0.07) 0.04 (0.02–0.06) 0.04 (0.03–0.06) 0.599
hsCRP (mg/L)c 6.3 (1.9–20.0) 3.4 (1.6–12.7) 3.5 (1.6–17.0) 7.8 (2.1–20.5) 9.2 (3.2–30.3) 0.016
BNP (pg/mL)c 193 (66–442) 35 (22–55) 117 (88–157) 295 (241–365) 707 (570–1196) <0.001
Risk factors
Current smoking, % (n) 15.6 (36) 26.3 (15) 8.5 (5) 14.0 (8) 13.8 (8) 0.058
Hypertension, % (n) 57.1 (132) 52.6 (30) 55.9 (33) 59.7 (34) 60.3 (35) 0.826
IDDM, % (n) 1.3 (3) 1.8 (1) 0 (0) 3.5 (2) 0 (0) 0.283
NIDDM, % (n) 30.3 (70) 24.6 (14) 30.5 (18) 40.4 (23) 25.9 (15) 0.245
eGFR (mL/min/1.73m2)b 61.2±28.8 76.1±20.9 62.0±31.6 57.3±29.5 49.4±25.7 <0.001
Hypercholesterolemia, % (n) 36.4 (84) 38.6 (22) 35.6 (21) 36.8 (21) 34.5 (20) 0.972
History of CHD
Angina pectoris, % (n) 42.0 (97) 36.8 (21) 39.0 (23) 45.6 (26) 46.6 (27) 0.650
MI, % (n) 28.1 (65) 10.5 (6) 25.4 (15) 42.1 (24) 34.5 (20) 0.001
CABG, % (n) 10.8 (25) 3.5 (2) 11.9 (7) 12.3 (7) 15.5 (9) 0.197
PCI, % (n) 10.8 (25) 10.5 (6) 11.9 (7) 10.5 (6) 10.3 (6) 0.993
History of heart failure
CHF, % (n) 34.2 (79) 19.3 (11) 27.1 (16) 38.6 (22) 51.7 (30) 0.002
Known CHD, % (n) 61.9 (143) 49.1 (28) 55.9 (33) 68.4 (39) 74.1 (43) 0.023
Treatment prior to admission
Beta blockers, % (n) 33.8 (78) 24.6 (14) 33.9 (20) 38.6 (22) 37.9 (22) 0.361
Index diagnosis
STEMI, % (n) 7.4 (17) 10.7 (6) 6.8 (4) 10.5 (6) 1.7 (1) 0.214
Country
Argentina, % (n) 47.2 (109) 57.9 (33) 61.0 (36) 42.1 (24) 27.6 (16) 0.001
aTotal cohort with available measurements: TnT; n=230, hsCRP; n=238, BNP; n=231.
bAge, eGFR, total cholesterol, HDL cholesterol, and triglycerides are given as mean±SD.
cPeak TnT, hsCRP, and BNP are given as median (quartiles Q1–Q3).
TnT, troponin-T; hsCRP, high-sensitive C-reactive protein; BNP, B-type natriuretic peptide; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent
diabetes mellitus; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention;
CHF, congestive heart failure; CHD, coronary heart disease; STEMI, ST-segment elevation myocardial infarction.
STATISTICAL ANALYSIS
Patients were divided into quartiles according to their BNP
and CRP levels. Approximately normally distributed variables
were given as mean and standard deviation (SD) whilst quar-
tiles were given for skewed continuous data. One way analy-
sis of variance and the Kruskal–Wallis test were used to test
for differences amongst groups of patients in the means of
normally distributed and medians of skewed data, respectively.
The Chi-square test for association was used to test for dif-
ferences in proportions amongst groups of patients. The haz-
ard ratios (HRs) comparing the lowest quartile to each of the
other quartiles from Cox regression models are presented with
95% confidence intervals (CIs). Separate stepwise Cox multi-
variable proportional hazards regression models with total and
cardiac death as the dependent variable were applied. The Cox
regression model contained BNP and CRP quartiles. In addition,
potential confounders added stepwise were: country, gender, age,
smoking, hypertension, STEMI, diabetes mellitus, CHF (defined
as Killip–Kimball class at admission; patients in class 2–4 were
classified as CHF patients and patients in class 1 were classified
as non-CHF), history of previous CHD [i.e., history of either
angina pectoris, MI, CABG, or percutaneous coronary interven-
tion (PCI)], hypercholesterolemia/use of statins, TnT, eGFR, and
beta-blocker use prior to enrollment. Subjects without an event
were censored at final follow-up. The Kaplan–Meier product lim-
its were used for plotting the times to event with the equality
of the survival curves assessed by the log-rank test. Hypothe-
sis p-values less than 0.05 two-sided are defined as statistically
significant.
RESULTS
A total of 239 patients presenting with chest-pain and suspected
ACS were selected in the present substudy based on a TnT value
>0.01 and ≤0.1 ng/mL. BNP or hsCRP samples were unavailable
www.frontiersin.org April 2015 | Volume 2 | Article 16 | 3
Nilsen et al. Risk assessment with borderline troponins
Table 2 | Baseline characteristics according to hsCRP (mg/L) quartiles.
Variable Total cohort a Q1 (n=58) Q2 (n=61) Q3 (n=59) Q4 (n=60) p-Value
Age, yearb 72.7±13.0 70.6±13.8 71.2±11.1 75.3±13.4 73.7±13.2 0.171
Male gender, % (n) 62.2 (148) 63.8 (37) 62.3 (38) 64.4 (38) 58.3 (35) 0.904
Risk markers at baseline
Peak TnT (ng/mL)c 0.04 (0.02–0.06) 0.05 (0.03–0.07) 0.04 (0.03–0.06) 0.04 (0.02–0.06) 0.04 (0.02–0.06) 0.256
hsCRP (mg/L)c 6.35 (1.90–20.0) 1.2 (0.5–1.6) 3.1 (2.4–4.6) 11.2 (8.3–16.0) 46.2 (29.8–132.8) <0.001
BNP (pg/mL)c 193 (65–443) 100 (51–283) 172 (64–372) 231 (72–473) 276 (104–567) 0.006
Risk factors
Current smoking, % (n) 15.5 (37) 12.1 (7) 16.4 (10) 10.2 (6) 23.3 (14) 0.200
Hypertension, % (n) 56.3 (134) 56.9 (33) 57.4 (35) 52.5 (31) 58.3 (35) 0.924
IDDM, % (n) 1.3 (3) 1.7 (1) 0 (0) 1.7 (1) 1.7 (1) 0.790
NIDDM, % (n) 29.8 (71) 24.1 (14) 31.2 (19) 33.9 (20) 30.0 (18) 0.702
eGFR (mL/min/1.73m2)b 61.3±28.5 67.7±27.9 64.4±25.2 60.9±27.6 52.3±31.2 0.020
Hypercholesterolemia, % (n) 35.7 (85) 48.3 (28) 42.6 (26) 27.1 (16) 25.0 (15) 0.017
History of CHD
Angina pectoris, % (n) 42.4 (101) 39.7 (23) 49.2 (30) 49.2 (29) 31.7 (19) 0.154
MI, % (n) 28.2 (67) 25.9 (15) 31.1 (19) 32.2 (19) 23.3 (14) 0.662
CABG, % (n) 10.9 (26) 10.3 (6) 16.4 (10) 5.1 (3) 11.7 (7) 0.262
PCI, % (n) angina 10.1 (24) 15.5 (9) 18.0 (11) 0 (0) 6.7 (4) 0.004
History of heart failure
CHF, % (n) 35.3 (84) 25.9 (15) 27.9 (17) 44.1 (26) 43.3 (26) 0.060
Known CHD, % (n) 62.6 (149) 58.6 (34) 67.2 (41) 66.1 (39) 58.3 (35) 0.632
Treatment prior to admission
Beta blockers, % (n) 33.6 (80) 37.9 (22) 45.9 (28) 30.5 (18) 20.0 (12) 0.020
Index diagnosis
STEMI, % (n) 7.2 (17) 6.9 (4) 13.3 (8) 3.4 (2) 5.0 (3) 0.163
Country
Argentina, % (n) 45.4 (108) 50.0 (29) 47.5 (29) 37.3 (22) 46.7 (28) 0.529
aTotal cohort with available measurements: TnT; n=230, hsCRP; n=238, BNP; n=231.
bAge, eGFR, total cholesterol, HDL cholesterol, and triglycerides are given as mean±SD.
cPeak TnT, hsCRP, and BNP are given as median (quartiles Q1–Q3).
TnT, troponin-T; HsCRP, high-sensitive C-reactive protein; BNP, B-type natriuretic peptide; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent
diabetes mellitus; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention;
CHF, congestive heart failure; CHD, coronary heart disease; STEMI, ST-segment elevation myocardial infarction.
for eight and one patient, respectively. Death information was not
available in one patient. In the Argentinean cohort, 59.6% had
TnT values>0.03 ng/mL as compared to 60.3% in the Norwegian
cohort. The corresponding proportion of patients with TnT values
>0.05 ng/mL was 36.7 and 35.5%, respectively.
The median BNP concentration in plasma was 193 (66–442)
pg/mL, 25 and 75 percentiles. The baseline characteristics of the
patients, stratified according to BNP quartiles at admission are
listed in Table 1. A TnT value >0.03 ng/mL was recorded in 151
subjects. TnT increased by at least 20% in 130 patients and by at
least 50% in 93 individuals. A drop in TnT by at least 20% and
50% was noted in 51 and 10 patients, respectively. Peak TnT levels
were similar in all quartiles of BNP. There were significant differ-
ences in the mean age and several other variables of the patients
across the four BNP quartiles. Patients in the highest quartile were
oldest on average. They were more often affected by previous heart
disease and CHF and had a significantly lower eGFR as compared
to patients in Q1. Their hsCRP was also increased and there was a
higher proportion of Norwegians than Argentineans in the highest
quartile of BNP.
The median hsCRP concentration in serum was 6.4 (1.9–20.0)
mg/mL, 25 and 75 percentiles. The baseline characteristics of the
patients, stratified according to hsCRP quartiles at admission are
listed in Table 2. There were significant differences in several vari-
ables across the four hsCRP quartiles. Patients with hsCRP in
the highest quartile were older and had a higher level of BNP
and a lower level of eGFR, and the proportion of patients on
β-blocker treatment was lower, as compared to Q1. A higher pro-
portion of patients in Q1 as compared to the higher quartiles had
undergone PCI.
ALL-CAUSE MORTALITY
After a follow-up period of 24 months, 69 patients (29.0%) had
died. Kaplan–Meier survival curves for the primary endpoint
according to BNP and hsCRP quartiles at baseline are presented
in Figures 1 and 2, respectively.
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FIGURE 1 | Kaplan–Meier plot of time to all-cause mortality within 2 years by BNP quartiles.
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FIGURE 2 | Kaplan–Meier plot of time to all-cause mortality within 2 years by hsCRP quartiles.
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FIGURE 3 | ROC for all-cause mortality at 2 years: BNP, CRP, andTnT.
The BNP levels were significantly higher among patients dying
than in survivors at 2 years [340 (142–656) versus 157 (58–367)
pg/mL (median, 25 and 75 percentiles),p< 0.001]. hsCRP was also
notably significantly higher among patients dying than in that of
survivors at 2 years [8.9 (3.4–34.6) versus 4.8 (1.6–17.8) mg/mL
(median, 25 and 75% percentiles), p= 0.004].
Receiver operated characteristics (ROC) curve for BNP, hsCRP,
and TnT are shown in Figure 3. The area under the ROC for
BNP was 0.676 (p< 0.001) and for hsCRP 0.621 (p= 0.004), as
compared to 0.489 (p= 0.803) for TnT.
The univariate HRs for total death were statistically significant
for both BNP and hsCRP, as shown in Table 3.
In a multivariable Cox regression model for total death within
2 years, the HR for BNP in the highest quartile (Q4) as compared to
the lowest (Q1) was 2.84 (95% CI, 1.13–7.17), p= 0.027 (Table 3),
in addition to age [HR 1.05 (95% CI, 1.02–1.08)], p< 0.001 and
hypercholesterolemia [HR 0.55 (95% CI, 0.31–0.98)], p= 0.043.
High-sensitive C-reactive protein rendered no significant prog-
nostic information for all-cause mortality; HR for the highest ver-
sus the lowest quartile 2.0 (95% CI,0.90–4.43),p= 0.089 (Table 3).
CARDIAC DEATH
After a follow-up period of 24 months, 38 deaths (16.5%) were
defined as cardiac. Kaplan–Meier survival curves according to BNP
and hsCRP quartiles at baseline are presented in Figures 4 and 5,
respectively.
Table 3 | Univariate and multivariate analysis.
All patients n=239
Univariatea Multivariatea
HR (95% CI), p-value HR (95% CI), p-value
BNP
Total death 4.60 (2.00–10.60), 0.001 2.84 (1.13–7.17), 0.027
Cardiac death 6.98 (2.05–23.85), 0.002 5.18 (1.06–25.26), 0.042
hsCRP
Death 3.10 (1.44–6.66), 0.004 2.00 (0.90–4.42), 0.089
Cardiac death 2.83 (0.995–8.02), 0.051 1.43 (0.48–4.25), 0.524
aHR, hazard ratio; 95% CI, confidence interval. Highest quartile (Q4) versus low-
est quartile (Q1). Cases with missing values in the multivariable analysis for total
death, n=12. Cases with missing values in the multivariable analysis for cardiac
death, n=20.
The ROC curves for BNP, hsCRP, and TnT are shown in
Figure 6. Area under the ROC for BNP was 0.687 (p< 0.001)
and for hsCRP, it was 0.614 (p= 0.031), as compared to 0.506
(p= 0.903) for TnT.
The univariate HRs for cardiac death was statistically signifi-
cant for BNP and borderline significant for hsCRP, as shown in
Table 3.
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FIGURE 4 | Kaplan–Meier plot of time to cardiac death within 2 years by BNP quartiles.
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FIGURE 5 | Kaplan–Meier plot of time to cardiac death within 2 years by hsCRP quartiles.
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In a multivariable Cox regression model for cardiac death
within 2 years, the HR for BNP was higher than for total mor-
tality [HR 5.18 (95% CI, 1.06–25.3)], p= 0.042 (Table 3). Age
[HR 1.12 (95% CI, 1.06–1.17), p< 0.001], CHF [HR 3.59 (95%
CI, 1.56–8.27), p= 0.003], STEMI [HR 4.38 (95% CI, 1.09–17.60),
p= 0.037], and country [HR 0.28 (95% CI, 0.11–0.69), p= 0.006]
also predicted outcome.
In a multivariable Cox regression model, hsCRP rendered no
significant prognostic information for cardiac mortality [HR 1.43
(95% CI, 0.48–4.25)], p= 0.53 (Table 3).
DISCUSSION
Continuous TnT values within the diagnostic borderline zone of
TnT yielded no additional prognostic information in the present
study,both in the univariate analysis, as reflected by the ROC curve,
and by the following multivariable analysis, whereas BNP was
found to be a substantial predictor of total and cardiac mortality.
Samples for TnT measurement were obtained at admission
and 6 h following hospitalization, providing a definite diagnosis
of myocardial injury (22–24). The highest TnT value within the
defined borderline zone was used for assessment of its prognos-
tic utility for future total and cardiac mortality. TnT increased by
at least 20% in more than a half of the population and dropped
by at least 20% in approximately 1/5 of the subjects. Thus, TnT
dynamics of this magnitude was present in approximately 75% of
the pooled population. A stable elevation of TnT in the remaining
patients may reflect more chronic conditions.
As early as 1992, the prognostic value of TnT as compared to
creatine kinase isoenzyme MB (CKMB) activity, was convincingly
demonstrated in UAP (25). In that study, TnT was detected in the
range of 0.20–3.64, median 0.50 ng/mL, which is above the studied
range in the present study. They employed a test kit with a sensi-
tivity of 0.20 ng/mL, whereas we used a TnT kit with a sensitivity
of 0.01 ng/mL. Several studies have shown that the level of TnT
contributes to risk stratification (26, 27). However, borderline val-
ues of TnT may reflect a variety of conditions, and sensitivity and
specificity is a challenge.
In a recent paper by Haaf and coworkers (23), high-sensitive
troponin-T (hsTnT) and fourth-generation TnT predicted 2-year
mortality in a prospective, international multicenter study includ-
ing 1117 unselected patients with chest-pain, of whom 82 (7.3%)
died during the observation period. In their study, blood was col-
lected at presentation to the ED and serially thereafter at 1, 2, 3,
and 6 h, whereas in our two pooled studies, conventional TnT was
measured at presentation to the ED and 6 h thereafter. In compar-
ison, our pooled cohort consisted of 1853 patients and during our
2-year follow-up, 257 (13.9%) patients had died. In the paper by
Haaf et al. (23), the risk of patients with negative conventional TnT
values, but elevated hsTnT at presentation, was found to be signif-
icantly increased. The prognostic pattern of hsTnT seems to differ
from that of conventional TnT, as its association with mortality
seems to be linear (23).
In the present study, we have focused on the prognostic
utility of conventional TnT (third- and fourth-generation) in
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chest-pain patients with borderline (0–6 h) values of TnT (>0.01
and≤0.1 ng/mL). Within this restricted interval, continuous TnT
values offered no additional prognostic information. Our subset
of patients with borderline TnT values consisted of 239 subjects
of whom 69 (29%) had died at 2-year follow-up, exceeding the
proportion of patients dying in the corresponding conventional
TnT zone in the study by Haaf et al. (23).
Elevated troponins indicate cardiac injury, but do not define the
cause of the injury (4). Thus, borderline TnT values ≤0.1 ng/mL
are not restricted to coronary events, but may also represent other
conditions such as stroke, pulmonary embolism (PE), sepsis, acute
perimyocarditis, Tako-tsubo, acute HF, and tachycardia.
Two-year mortality in our subset of patients with borderline
TnT was not predicted by the level of this myocardial injury bio-
marker, which clearly confirms the importance of adding other
biomarkers for risk assessment in this zone of TnT. Thus, by
adding BNP and hsCRP, the former was found to be independently
associated with both total and cardiac mortality in our quartile
multivariable model. Furthermore, we found that the prognostic
utility of hsCRP reached statistical significance in the univariate
analysis, but this biomarker did not behave as an independent
predictor in the multivariable analysis.
Our results are in line with the recommendations in the ESC
guidelines (25). As stated in these guidelines, cardiac troponins
are the key biomarkers for initial risk stratification, whereas other
biomarkers, such as BNP (28, 29) and hsCRP (30, 31), may provide
incremental prognostic information.
BNP is not only released in HF (6–8), but also by myocardial
ischemia (32–34) and by lung embolism (35). Retrospective data
in patients with NSTE-ACS (29) show that elevated BNP or NT-
proBNP levels are associated with a significantly increased mortal-
ity rate as compared to lower levels, independent of troponin and
hsCRP measurements.
Cut-off levels of BNP vary according to presenting symp-
toms and age. A cut-off value of 100 pg/mL has a strong negative
predictive value, ruling out a diagnosis of HF (36).
In the present prospective study, BNP values in the upper quar-
tile(s) were clearly elevated and the rate of CHF was almost three
times as high in the upper as compared to the lower quartile. In
fact, there was a graded increase in CHF across the quartiles of
BNP from Q1 to Q4. These findings are expected, as BNP is a
confirmed marker of heart insufficiency. However, as BNP was
found to be an independent marker of survival, other factors, as
mentioned above, may contribute. Thus, natriuretic peptide mea-
surements on admission or during hospitalization are useful for
risk stratification irrespective of the cause (24, 37).
Limitations: our results are limited to two chest-pain popula-
tions, from Norway and from Argentina, respectively. Both BNP
and hsCRP are based on one single blood sample obtained upon
admission, whereas TnT was measured twice, at admission and 6 h
later. We did not include recordings of LVEF in this study. Patients
with CHF included patients with known HF, categorized by NYHA
class II–IV (12), or those with Killip class 2–4 on admission, as
previously described (13). Patients with CHF accounted for 35.3%
of the population. Both BNP and hsCRP values in the present study
mirror high age as well as a higher burden of disease, including
CHF and reduced renal function.
Inclusions and follow-up were based on the same CRF and the
2-year follow-up program was completed within the same decade.
We have not presented further diagnostic and angiographic infor-
mation, as the aim of this study was to investigate the prognostic
contribution of the studied biomarkers, irrespective of etiology.
As reperfusion therapy in STEMIs may influence outcome, this
should be mentioned. Only 42% of the total Argentinean STEMI
cohort received this treatment (13) as compared to the general
use of reperfusion therapy in Norway. As only 7.1% of the pooled
patients in the present study presented with a STEMI, the propor-
tion of patients not receiving reperfusion therapy was low and of
less importance to the interpretation of results.
In conclusion, TnT may be a useful tool for stratifying patients
at risk, but borderline admission levels of this biomarker were
not found to yield additional prognostic information during a 2-
year follow-up period. However, within the selected TnT range,
the upper as compared to the lower quartile of BNP predicted
total and cardiac mortality after adjusting for covariables, whereas
hsCRP was not found to be an independent predictor in our mul-
tivariable model. BNP should be assessed routinely in patients
with borderline TnT values and an increase in BNP should lead to
further clinical investigation.
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